中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
16期
78-79,80
,共3页
二甲双胍%非酒精性脂肪肝%组织学%超声影像学%安全性
二甲雙胍%非酒精性脂肪肝%組織學%超聲影像學%安全性
이갑쌍고%비주정성지방간%조직학%초성영상학%안전성
metformin%non-alcobolic fatty liver%bistology%safety
目的：探讨二甲双胍对非酒精性脂肪肝（NAFLD）患者肝脏组织学及超声影像学的影响。方法将118例患者随机分为对照组和观察组，各59例。两组患者均给予健康教育，对照组患者给予阿托伐他汀治疗，观察组患者在对照组治疗基础上加用二甲双胍，疗程均为8周。结果治疗后，观察组患者空腹血糖、胰岛素水平及胰岛素抵抗指数均较前明显下降（ P<0.05）；两组患者炎症评分均较治疗前明显下降，且观察组下降程度更明显（ P<0.05）；仅观察组纤维化指标评分较治疗前有明显下降（ P<0.05），其肝脏肋下斜径较治疗前明显减小（ P<0.05）；两组患者治疗过程中药品相关不良反应发生情况无明显差异（ P>0.05）。结论二甲双胍能有效减轻NAFLD患者的胰岛素抵抗，对减轻肝细胞炎性反应和预防纤肝维化有明显作用，也能有效防止肝脏体积的增大，且不良反应较低，安全性良好。
目的：探討二甲雙胍對非酒精性脂肪肝（NAFLD）患者肝髒組織學及超聲影像學的影響。方法將118例患者隨機分為對照組和觀察組，各59例。兩組患者均給予健康教育，對照組患者給予阿託伐他汀治療，觀察組患者在對照組治療基礎上加用二甲雙胍，療程均為8週。結果治療後，觀察組患者空腹血糖、胰島素水平及胰島素牴抗指數均較前明顯下降（ P<0.05）；兩組患者炎癥評分均較治療前明顯下降，且觀察組下降程度更明顯（ P<0.05）；僅觀察組纖維化指標評分較治療前有明顯下降（ P<0.05），其肝髒肋下斜徑較治療前明顯減小（ P<0.05）；兩組患者治療過程中藥品相關不良反應髮生情況無明顯差異（ P>0.05）。結論二甲雙胍能有效減輕NAFLD患者的胰島素牴抗，對減輕肝細胞炎性反應和預防纖肝維化有明顯作用，也能有效防止肝髒體積的增大，且不良反應較低，安全性良好。
목적：탐토이갑쌍고대비주정성지방간（NAFLD）환자간장조직학급초성영상학적영향。방법장118례환자수궤분위대조조화관찰조，각59례。량조환자균급여건강교육，대조조환자급여아탁벌타정치료，관찰조환자재대조조치료기출상가용이갑쌍고，료정균위8주。결과치료후，관찰조환자공복혈당、이도소수평급이도소저항지수균교전명현하강（ P<0.05）；량조환자염증평분균교치료전명현하강，차관찰조하강정도경명현（ P<0.05）；부관찰조섬유화지표평분교치료전유명현하강（ P<0.05），기간장륵하사경교치료전명현감소（ P<0.05）；량조환자치료과정중약품상관불량반응발생정황무명현차이（ P>0.05）。결론이갑쌍고능유효감경NAFLD환자적이도소저항，대감경간세포염성반응화예방섬간유화유명현작용，야능유효방지간장체적적증대，차불량반응교저，안전성량호。
Objective To investigate influence of metformin on liver bistology and ultrasonograpby in patients witb non-alcobolic fatty liver disease(NAFLD). Methods Totally 118 patients witb NAFLD were randomly divided into control group and observation group,59 cases in eacb group. Two groups of patients were giver bealtb education,on tbis basis tbe control group were treated witb atorvastatin, tbe observation group on tbe basis of control group were added metformin,tbe treatment course was 8 weeks. Results After treatment, tbe FPG,insulin levels and insulin resistance index in tbe observation group were significantly decreased tban before treatment( P <0. 05);tbe inflammatory scores in tbe two groups were significantly decreased tban before treatment,moreover tbe observation group de-creased more significantly( P < 0. 05);bowever,compared witb before treatment,only in tbe observation group tbe fibrosis score were significantly decreased( P < 0. 05),tbe liver subcostal oblique diameter was significantly reduced( P < 0. 05);tbe occurrence rate of adverse drug reactions during tbe treatment course bad no significant difference between tbe two groups( P > 0. 05). Conclusion Met-formin can effectively reduce insulin resistance in patients witb NAFLD,reduce tbe inflammatory response of liver cells and prevent fi-brosis,and can effectively prevent tbe increase of tbe liver volume witb less adverse reactions and good safety.
